primary studies - published RCT

Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study.

Code: PM22968159 **Year:** 2012 **Date:** 2012 **Author:** Furnari ML

Study design (if review, criteria of inclusion for studies)

prospective, randomized, double-blind, parallel-group, controlled study

Participants

patients with cystic fibrosis and lung disease

Interventions

a hypertonic saline solution containing hyaluronic acid (Hyaneb) versus standard hypertonic saline

Outcome measures

tolerability of hypertonic saline

Main results

The results showed that nebulized Hyaneb was more effective in reducing the need for beta(2) bronchodilators and caused a significant reduction in the incidence of adverse effects compared with nebulized hypertonic saline solution alone. Its safety profile indicates that Hyaneb can be used for the treatment of lung disease in cystic fibrosis.

http://dx.doi.org/10.1177/1753465812458984

See also

Ther Adv Respir Dis. 2012 Sep 11.

Keywords

Adolescent; Child; hyaluronic acid; hydration; Hypertonic Solutions; Inhalation OR nebulised; pharmacological_intervention; Airway clearance drugs -expectorants- mucolytic- mucociliary-; Respiratory System Agents;